ProSomnus Receives FDA Clearance for First Theragnostic Sleep Apnea Device Combining Oral Therapy with Continuous Monitoring
Key Insights
ProSomnus Sleep Technologies (search) received FDA Class II 510(k) clearance for the RPMO₂ OSA Device (search), marking the first theragnostic device for sleep medicine that integrates precision oral appliance therapy with multi-night physiologic monitoring.
The device features an embedded oximeter that uses buccal mucosa for measurements, demonstrating strong clinical accuracy with 2.94% ARMS for SpO₂ (search) and no systematic bias across skin pigmentation groups in validation studies.
The FDA clearance enables Smart Sleep Medicine workflows, allowing clinicians to monitor OSA (search) treatment continuously and make data-driven adjustments rather than relying on subjective patient feedback.
ProSomnus Sleep Technologies (search) announced that the U.S. Food and Drug Administration (search) has granted Class II 510(k) clearance for its RPMO₂ OSA Device (search), representing a breakthrough in sleep medicine technology. The device is the first theragnostic platform to combine precision oral appliance therapy with continuous physiologic monitoring in a single integrated system.
The FDA clearance under product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765) confirms that the RPMO₂ OSA Device (search) meets federal standards for safety and effectiveness in measuring oxygen saturation (search) (SpO₂ (search)) and pulse rate (search). This milestone positions the device as a cornerstone technology for what ProSomnus terms "Smart Sleep Medicine"—a connected, evidence-driven approach to managing obstructive sleep apnea (search) as a chronic disease.
Revolutionary Design and Clinical Validation
The RPMO₂ OSA Device (search) features a wholly embedded oximeter encapsulated in an overlay of the maxillary dentition, utilizing the mucosa of the buccal vestibule behind the upper lip as the reflective tissue for measurements. Data are transmitted securely to a provider portal via a patient smartphone application, enabling real-time monitoring and care coordination.
The device's FDA clearance is supported by rigorous validation research conducted at the University of Calgary and published by Snow et al. in 2025. The gold standard study evaluated the accuracy of the intraoral buccal mucosal oximeter against arterial oxyhemoglobin saturation measured using CO oximetry, the clinical gold standard for oxygen saturation (search) measurement.
The comprehensive controlled desaturation study enrolled 12 healthy adults, consistent with ISO 80601 2 61 requirements, and included participants with a spectrum of skin pigmentation. Participants underwent six precisely controlled hypoxic plateaus spanning approximately 97% to 72% SaO₂, with analysis performed on 325 SaO₂/SpO₂ (search) data pairs and 346 pulse rate (search)/ECG data pairs.
Superior Accuracy Across Diverse Populations
The RPMO₂ OSA Device (search) demonstrated strong clinical accuracy across the full range of 70-100% SaO₂, with an Accuracy Root Mean Square (ARMS) for SpO₂ (search) of 2.94% and a correlation between SpO₂ and SaO₂ of r = 0.95. Bland-Altman analysis revealed a mean bias of 0.72, with upper and lower 95% limits of agreement of 6.31 and -4.86, respectively.
Importantly, the study reported no systematic bias across skin pigmentation groups. The buccal mucosa, which contains less melanin than the epidermis, may reduce the overestimation of oxygen saturation (search) seen in conventional fingertip devices that measure through melanin-rich tissue.
For pulse rate (search) measurement, the device achieved excellent performance with an ARMS of 2.08 beats per minute and a correlation between pulse rate and ECG of r = 0.99. Bland-Altman analysis showed a mean bias of 0.30, with upper and lower 95% limits of agreement of 4.34 and -3.73, respectively.
Addressing Conventional Oximetry Limitations
The innovative intraoral design addresses several recognized limitations of conventional pulse oximeters. The stable placement high in the buccal vestibule minimizes motion-induced noise, while the richly vascularized buccal mucosa supports high-quality photoplethysmography. The temperature-stable intraoral environment avoids temperature-dependent perfusion variability, and the vestibular location provides intrinsic light shielding from ambient light interference.
"The RPMO₂ OSA Device (search) represents years of innovation in engineering, human centric design, and rigorous scientific validation," commented Sung Kim, ProSomnus Chief Technology Officer. "We set out to create a miniature, highly accurate, comfortable oximeter capable of real-world performance. FDA clearance confirms that we achieved this goal and opens the door to continuous insight into patient physiology."
Clinical Impact and Expert Perspectives
The clearance enables clinicians to pair precision oral appliance therapy with continuous, longitudinal physiologic monitoring for the first time. This capability supports data-driven treatment adjustments and mitigates limitations of single-night testing, positioning sleep apnea care alongside modern chronic disease management paradigms.
"The ProSomnus RPMO₂ OSA Device (search) stands to elevate the practice of sleep medicine by simplifying device titration by allowing for the use of robust, objective SpO₂ (search) data to guide device titration where previously subjective patient feedback has been used," noted Erin Mosca, PhD, ProSomnus Director of Scientific and Medical Affairs.
Dr. Sanjay V. Patel emphasized the device's potential to address healthcare disparities: "The application of oximetry to the buccal mucosa bypasses concerns of oximetry accuracy on pigmented skin and so should help reduce existing racial disparities in sleep apnea care. I am excited about the potential that RPMO₂ has to improve the care of my patients with sleep apnea."
Enabling Smart Sleep Medicine
The FDA clearance unlocks ProSomnus's Smart Sleep Medicine platform, enabling longitudinal physiologic monitoring across nights and treatment stages, evidence-based connected care workflows including remote physiologic monitoring (RPM), and real-world insights for personalizing precision oral appliance therapy.
"By integrating safe, accurate, continuous physiologic measurement into our precision oral appliance platform, we are enabling Smart Sleep Medicine—a connected, data driven model that helps clinicians manage sleep apnea as the personal, individualized and chronic disease it truly is," stated Len Liptak, Chief Executive Officer of ProSomnus.
The technology addresses a significant global health challenge, with obstructive sleep apnea (search) affecting over 1 billion people worldwide and linked to life-threatening comorbidities including heart failure (search), stroke (search), and type 2 diabetes (search). ProSomnus precision devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, and TRICARE, representing over 200 million covered lives globally.